Protagonist Therapeutics, Inc
PTGX
$0.00
+5.15%
Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, peptide-based therapeutics for inflammation and immunology, hematology, and metabolic diseases. The company's distinct identity is built on its proprietary technology platform for designing oral peptides, positioning it as a potential disruptor in biologics-dominated therapeutic areas. The current investor narrative is overwhelmingly driven by the recent FDA approval of its partnered oral psoriasis drug, icotyde (icotrokinra), with Johnson & Johnson, which validates the platform and introduces a significant commercial catalyst, alongside ongoing pivotal studies for rusfertide in polycythemia vera that could establish another major growth pillar.…
PTGX
Protagonist Therapeutics, Inc
$0.00
Related headlines
PTGX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Protagonist Therapeutics, Inc's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
6 analysts
Implied Upside
—
vs. current price
Analyst Count
6
covering this stock
Price Range
$0 - $0
Analyst target range
The stock is covered by 6 analysts, and institutional sentiment is uniformly bullish, as evidenced by a series of recent 'Buy' or 'Overweight' ratings from firms including Leerink Partners, JP Morgan, Barclays, and Citigroup in March 2026. The consensus recommendation is a 'Buy', though a specific average target price is not provided in the data, preventing a calculation of implied upside or downside from the current price of $122.63. The target price range is also not specified in the data, but the wide dispersion in analyst revenue estimates—with a low of $420.9 million and a high of $808.8 million for the next period—signals high uncertainty and debate around the commercial uptake and peak sales potential of icotyde and rusfertide. The high-end estimates likely assume rapid market penetration and label expansions, while the low-end may price in competitive threats or slower adoption. The recent flurry of reaffirmed bullish ratings following the FDA approval indicates strong near-term conviction, but the lack of a quantified target range limits the precision of this signal.
Bulls vs Bears: PTGX Investment Factors
The bull case, currently supported by stronger near-term evidence, is driven by the transformative FDA approval of icotyde, a robust balance sheet, and powerful technical momentum. The bear case is anchored in an extreme valuation that leaves no room for error, a lack of current profitability, and high volatility. The single most important tension in the investment debate is whether the company can rapidly translate its FDA approval into the blockbuster sales growth (from $7.44M quarterly to a projected $692.8M annual run-rate) required to justify its 120.66x PS multiple. The resolution of this commercial execution risk will determine the stock's direction.
Bullish
- FDA Approval of Icotyde: The FDA approval of the oral psoriasis drug icotyde (icotrokinra), partnered with Johnson & Johnson, is a transformative validation event. It provides a clear commercial catalyst and de-risks the company's proprietary oral peptide platform, which is a key driver of the stock's 125% 1-year gain.
- Strong Financial Position: The company has a fortress balance sheet with a current ratio of 12.71 and a negligible debt-to-equity ratio of 0.017, providing ample liquidity to fund its pivotal clinical programs. This low leverage and high cash position significantly reduce near-term financing risk.
- High-Growth Revenue Pipeline: Analyst consensus projects next-period revenue to average $692.8 million, representing a massive leap from the current quarterly run-rate of $7.44 million. This growth is underpinned by the commercial launch of icotyde and the potential of rusfertide in polycythemia vera.
- Unanimous Analyst Bullishness: All 6 covering analysts have issued 'Buy' or 'Overweight' ratings, reflecting strong institutional conviction in the company's near-term prospects following the FDA approval. This consensus suggests a high degree of confidence in the commercial and clinical narrative.
Bearish
- Extreme Valuation Multiples: The stock trades at a stratospheric trailing Price-to-Sales (PS) ratio of 120.66x, which prices in near-perfect execution of blockbuster sales. This leaves the stock vulnerable to severe multiple contraction if revenue growth disappoints or is delayed.
- No Current Profitability: The company is deeply unprofitable, with a net loss of -$44.38 million in Q4 2025 and a negative ROE of -21.17%. Operating losses are widening sequentially as R&D expenses ramp to $46.36 million, indicating a high cash burn rate ahead of commercialization.
- Lumpy, Event-Driven Revenue: Current revenue is minimal and highly volatile, dropping -95.64% YoY in the latest quarter to $7.44 million due to the absence of a large milestone payment. This underscores the binary, pre-commercial nature of the business and lack of recurring sales.
- High Beta and Volatility: With a beta of 1.83, the stock is 83% more volatile than the market, making it highly sensitive to broader risk-off sentiment. This elevated volatility, combined with its recent 125% run-up, increases the risk of a sharp correction on any negative news.
PTGX Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a 125.26% gain over the past year. As of the latest close at $122.63, the price is trading at approximately 97% of its 52-week high of $126.19, indicating it is near the peak of its recent range and reflecting strong bullish momentum and potential overextension. The stock's beta of 1.83 signals it is 83% more volatile than the broader market, which is typical for a clinical-stage biotech and necessitates larger risk tolerance from investors. Recent short-term momentum is exceptionally strong and accelerating, with the stock up 22.65% over the past month and 23.91% over the past three months, far outpacing the SPY's returns of -2.17% and 15.8%, respectively. This divergence from the market and the 1-year trend suggests the stock is being driven by powerful company-specific catalysts, such as the recent FDA approval, rather than broader market movements. The relative strength index (RSI) data is not explicitly provided, but the magnitude of the moves and the 1-month relative strength of 24.82% indicate heavily overbought conditions. Key technical levels are clear, with immediate resistance at the 52-week high of $126.19 and support at the 52-week low of $49.38. A decisive breakout above $126.19 would signal a continuation of the uptrend and likely target new all-time highs, while a breakdown below the recent consolidation range near $100 would suggest profit-taking and a potential trend reversal. The stock's high beta of 1.83 underscores its sensitivity to both positive news and market-wide risk-off sentiment, making position sizing critical.
Beta
1.79
1.79x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$49-$132
Price range past year
Annual Return
+159.7%
Cumulative gain past year
| Period | PTGX Return | S&P 500 |
|---|---|---|
| 1m | +41.2% | -1.3% |
| 3m | +26.8% | +13.6% |
| 6m | +51.0% | +9.0% |
| 1y | +159.7% | +19.1% |
| ytd | +51.0% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PTGX Fundamental Analysis
Revenue is currently minimal and highly volatile, driven by collaboration milestones rather than product sales, with the most recent quarterly revenue at $7.44 million, representing a staggering -95.64% year-over-year decline. This sharp drop is due to the recognition of a large $170.64 million milestone payment in Q4 2024, compared to a smaller $7.44 million in development services revenue in Q4 2025; the underlying trend is one of lumpy, event-driven revenue typical of pre-commercial biotechs awaiting product launches. The company is not yet profitable on a net income basis, reporting a net loss of -$44.38 million in Q4 2025, though it maintains an exceptionally high gross margin of 94.94% on its development services. Operating losses have widened sequentially from -$19.31 million in Q1 2025 to -$50.36 million in Q4 2025 as R&D expenses ramped up to $46.36 million in the latest quarter, indicating heavy investment in the clinical pipeline ahead of potential commercialization. The balance sheet remains robust with a strong current ratio of 12.71 and a minimal debt-to-equity ratio of 0.017, indicating ample liquidity and low financial leverage. Trailing twelve-month free cash flow is positive at $57.67 million, but quarterly operating cash flow was negative -$36.98 million in Q4 2025, highlighting that while the company has a cash runway from past collaborations, it is currently burning cash to fund operations. The return on equity of -21.17% reflects the current loss-making phase of investing in clinical development.
Quarterly Revenue
$7437000.0B
2025-12
Revenue YoY Growth
-0.95%
YoY Comparison
Gross Margin
+0.94%
Latest Quarter
Free Cash Flow
$57671000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PTGX Overvalued?
Given the company's negative net income and negative EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is an extraordinarily high 120.66x, reflecting the market's valuation of future sales potential from the recently approved icotyde and the rusfertide pipeline rather than current negligible revenue. A forward PS ratio is not calculable from the provided data, but analyst revenue estimates for the next period average $692.8 million, which would imply a significant compression in the multiple if achieved. Peer comparison is challenging as industry average multiples are not provided in the data. However, a PS ratio of 120.66x is stratospheric by any standard and indicates the market is pricing in near-perfect execution and blockbuster sales for its lead assets. This premium is justified only by the transformative potential of its recently FDA-approved oral peptide and the high unmet need in its target markets; any clinical or commercial misstep would likely trigger a severe multiple contraction. Historically, the stock's own valuation has soared. The current PS ratio of 120.66x is dramatically higher than its levels from just a few quarters ago, such as 14.10x at the end of 2024 and 746.60x at the end of 2025 (on very low revenue). Trading near the top of its own historical valuation band suggests extreme optimism is baked into the price, leaving little room for error and increasing downside risk if growth expectations are not met rapidly.
PE
-42.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -65x~13x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-42.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Protagonist faces significant financial risks stemming from its pre-commercial stage. The company is burning cash, with quarterly operating cash flow of -$36.98M in Q4 2025, and net losses are widening sequentially as R&D expenses ramp to $46.36M. Revenue is currently negligible and highly volatile, dropping -95.64% YoY, demonstrating complete dependence on milestone payments and future product sales rather than a stable revenue stream. While the balance sheet is strong now, the cash burn rate necessitates that commercial launches succeed to avoid future dilutive financing.
Market & Competitive Risks: The primary market risk is valuation compression. Trading at a PS ratio of 120.66x, the stock is priced for flawless execution. Any disappointment in icotyde's launch trajectory or rusfertide's clinical data could trigger a severe derating. The stock's high beta of 1.83 makes it acutely sensitive to sector-wide biotech sell-offs and rising interest rates, which compress the present value of long-dated future cash flows. Furthermore, the recent FDA approval introduces icotyde into a competitive psoriasis market dominated by established biologics, creating commercial execution and market share risks.
Worst-Case Scenario: The worst-case scenario involves a combination of a slower-than-expected icotyde launch, a clinical setback for rusfertide, and a broader biotech market downturn. This could lead to a rapid unwinding of the extreme optimism priced into the stock, triggering analyst downgrades and a flight to safety. A realistic downside could see the stock re-testing its 52-week low of $49.38, representing a potential loss of approximately -60% from the current price of $122.63. The high short ratio of 14.18 indicates a cohort of investors is already positioned for such a decline.